The next-generation RNA therapeutics market is advancing rapidly with innovations in RNA-based drugs targeting cancer, genetic disorders, and infectious diseases, driving strong growth and adoption. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Next-Generation RNA Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Next-Generation RNA Therapeutics Market, by Therapy Type
8.1.1. mRNA-Based Therapeutics
8.1.1.1. Market Revenue and Forecast
8.1.2. Circular RNA (circRNA)
8.1.2.1. Market Revenue and Forecast
8.1.3. Self-Amplifying RNA (saRNA)
8.1.3.1. Market Revenue and Forecast
8.1.4. RNA Interference (RNAi)
8.1.4.1. Market Revenue and Forecast
8.1.5. RNA Aptamers
8.1.5.1. Market Revenue and Forecast
8.1.6. Small Activating RNA (saRNA)
8.1.6.1. Market Revenue and Forecast
9.1. Next-Generation RNA Therapeutics Market, by Application
9.1.1. Infectious Diseases
9.1.1.1. Market Revenue and Forecast
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast
9.1.3. Rare Genetic Disorders
9.1.3.1. Market Revenue and Forecast
9.1.4. Cardiovascular Diseases
9.1.4.1. Market Revenue and Forecast
9.1.5. Neurological Disorders
9.1.5.1. Market Revenue and Forecast
9.1.6. Autoimmune & Inflammatory Conditions
9.1.6.1. Market Revenue and Forecast
10.1. Next-Generation RNA Therapeutics Market, by Delivery Mechanism
10.1.1. Lipid Nanoparticles (LNPs)
10.1.1.1. Market Revenue and Forecast
10.1.2. Polymer-Based Nanocarriers
10.1.2.1. Market Revenue and Forecast
10.1.3. Extracellular Vesicles (EVs)
10.1.3.1. Market Revenue and Forecast
10.1.4. Viral Vectors
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Next-Generation RNA Therapeutics Market, by End-User
11.1.1. Biopharmaceutical Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Research & Manufacturing Organizations (CROs/CMOs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Research Institutes
11.1.3.1. Market Revenue and Forecast
11.1.4. Hospitals & Specialty Clinics
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type
12.1.2. Market Revenue and Forecast, by Application
12.1.3. Market Revenue and Forecast, by Delivery Mechanism
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type
12.1.5.2. Market Revenue and Forecast, by Application
12.1.5.3. Market Revenue and Forecast, by Delivery Mechanism
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type
12.1.6.2. Market Revenue and Forecast, by Application
12.1.6.3. Market Revenue and Forecast, by Delivery Mechanism
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type
12.2.2. Market Revenue and Forecast, by Application
12.2.3. Market Revenue and Forecast, by Delivery Mechanism
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type
12.2.5.2. Market Revenue and Forecast, by Application
12.2.5.3. Market Revenue and Forecast, by Delivery Mechanism
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type
12.2.6.2. Market Revenue and Forecast, by Application
12.2.6.3. Market Revenue and Forecast, by Delivery Mechanism
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type
12.2.7.2. Market Revenue and Forecast, by Application
12.2.7.3. Market Revenue and Forecast, by Delivery Mechanism
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type
12.2.8.2. Market Revenue and Forecast, by Application
12.2.8.3. Market Revenue and Forecast, by Delivery Mechanism
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type
12.3.2. Market Revenue and Forecast, by Application
12.3.3. Market Revenue and Forecast, by Delivery Mechanism
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type
12.3.5.2. Market Revenue and Forecast, by Application
12.3.5.3. Market Revenue and Forecast, by Delivery Mechanism
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type
12.3.6.2. Market Revenue and Forecast, by Application
12.3.6.3. Market Revenue and Forecast, by Delivery Mechanism
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type
12.3.7.2. Market Revenue and Forecast, by Application
12.3.7.3. Market Revenue and Forecast, by Delivery Mechanism
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type
12.3.8.2. Market Revenue and Forecast, by Application
12.3.8.3. Market Revenue and Forecast, by Delivery Mechanism
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type
12.4.2. Market Revenue and Forecast, by Application
12.4.3. Market Revenue and Forecast, by Delivery Mechanism
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type
12.4.5.2. Market Revenue and Forecast, by Application
12.4.5.3. Market Revenue and Forecast, by Delivery Mechanism
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type
12.4.6.2. Market Revenue and Forecast, by Application
12.4.6.3. Market Revenue and Forecast, by Delivery Mechanism
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type
12.4.7.2. Market Revenue and Forecast, by Application
12.4.7.3. Market Revenue and Forecast, by Delivery Mechanism
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type
12.4.8.2. Market Revenue and Forecast, by Application
12.4.8.3. Market Revenue and Forecast, by Delivery Mechanism
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type
12.5.2. Market Revenue and Forecast, by Application
12.5.3. Market Revenue and Forecast, by Delivery Mechanism
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type
12.5.5.2. Market Revenue and Forecast, by Application
12.5.5.3. Market Revenue and Forecast, by Delivery Mechanism
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type
12.5.6.2. Market Revenue and Forecast, by Application
12.5.6.3. Market Revenue and Forecast, by Delivery Mechanism
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. Alnylam Pharmaceuticals
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Arcturus Therapeutics
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Arrowhead Pharmaceuticals
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. AstraZeneca
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. BioNTech SE
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Chimeron Bio
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. CureVac AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. eTheRNA Immunotherapies
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Gilead Sciences
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Ionis Pharmaceuticals
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description